Esophageal Cancer Molecular Diagnostics Market Share

  • Report ID: 6129
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Esophageal Cancer Molecular Diagnostics Market Share

APAC Market Statistics

Asia Pacific in esophageal cancer molecular diagnostics market is anticipated to account for more than 60% revenue share by the end of 2036. The market growth in the region is also expected on account of a lack of awareness of the symptoms and a lifestyle that causes high inflammation in the body. In many of these countries, access to good healthcare is limited. Along with uninhibited use of tobacco, and alcohol, low income, and various vitamin deficiencies, the inhabitants face an increased risk of oesophageal cancer.

In China, the market is expanding meteorically, to suppress the alarming mortality rates of oesophageal cancer. These developments result in a bigger space for the esophageal cancer molecular diagnostics market to grow. Korea has seen a significant development in diagnosing esophageal cancers early for a better prognosis and is expected to further rely on diagnostics technology to shrink the mortality percentage further

North America Market Statistics

By the end of 2036, North American esophageal cancer molecular diagnostics market is predicted to capture around 20% share owing to the increasing frequency of obesity and high alcohol use in the region. Barret’s oesophagus is also a risk factor that will increase the cases of oesophageal cancer in the region, specifically in North America. The government here is doubling its investments in healthcare with the latest innovations in the field of medicine. It encourages people to get better healthcare and diagnosis early.

Top market players are expected to invest in technological advancements to increase early diagnosis. Better diagnostics lead to an increase in the number of oesophageal cancers, which are mostly diagnosed in the advanced stages. More common in Caucasians, it accounts for 2% of the cause of death in North America. One can expect moderate growth in revenue in this area.

Research Nester
Esophageal Cancer Molecular Diagnostics Market Share
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6129
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of esophageal cancer molecular diagnostics was over USD 4 billion.

The market size for esophageal cancer diagnostics is forecasted to cross USD 11.54 billion by the end of 2036 expanding at a CAGR of 7.65% in the predicted timeline mentioned i.e., between 2024-2036.

The major players in the market are Roche Diagnostics, Chordia Therapeutics, Otsuka Pharmaceutical Co., Ltd, Agilent Technologies, Inc., Thermo Fisher Scientific, Illumina Inc., and others.

The genetic tests segment is anticipated to achieve a share/size of 55% during 2024-2036.

The Asia Pacific esophageal cancer molecular diagnostics sector is poised to hold a 60% share by the end of 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample